JP2008533007A5 - - Google Patents

Download PDF

Info

Publication number
JP2008533007A5
JP2008533007A5 JP2008500729A JP2008500729A JP2008533007A5 JP 2008533007 A5 JP2008533007 A5 JP 2008533007A5 JP 2008500729 A JP2008500729 A JP 2008500729A JP 2008500729 A JP2008500729 A JP 2008500729A JP 2008533007 A5 JP2008533007 A5 JP 2008533007A5
Authority
JP
Japan
Prior art keywords
sdz
rad isomer
rad
isomer
organic solvent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2008500729A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008533007A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2006/006125 external-priority patent/WO2006096325A1/en
Publication of JP2008533007A publication Critical patent/JP2008533007A/ja
Publication of JP2008533007A5 publication Critical patent/JP2008533007A5/ja
Withdrawn legal-status Critical Current

Links

JP2008500729A 2005-03-07 2006-02-22 42−o−(2−ヒドロキシ)エチル−ラパマイシンのオキセパン異性体 Withdrawn JP2008533007A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US65937805P 2005-03-07 2005-03-07
PCT/US2006/006125 WO2006096325A1 (en) 2005-03-07 2006-02-22 Oxepane isomer of 42-o-(2-hydroxy)ethyl-rapamycin

Publications (2)

Publication Number Publication Date
JP2008533007A JP2008533007A (ja) 2008-08-21
JP2008533007A5 true JP2008533007A5 (enExample) 2009-04-09

Family

ID=36572419

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008500729A Withdrawn JP2008533007A (ja) 2005-03-07 2006-02-22 42−o−(2−ヒドロキシ)エチル−ラパマイシンのオキセパン異性体

Country Status (9)

Country Link
US (1) US7241771B2 (enExample)
EP (1) EP1856131A1 (enExample)
JP (1) JP2008533007A (enExample)
CN (1) CN101137659A (enExample)
AU (1) AU2006221024A1 (enExample)
BR (1) BRPI0608885A2 (enExample)
CA (1) CA2602010A1 (enExample)
MX (1) MX2007010892A (enExample)
WO (1) WO2006096325A1 (enExample)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2008120670A (ru) * 2005-12-07 2010-01-20 Вайет (Us) Масштабируемый способ получения 42-сложного эфира рапамицина из 42-сложного эфира рапамицина бороната
KR20080077618A (ko) * 2005-12-07 2008-08-25 와이어쓰 정제된 결정체 cci-779 의 제조 방법
RU2008120712A (ru) * 2005-12-07 2010-01-20 Вайет (Us) Способы получения кристаллического рапамицина и определения кристалличности соединений рапамицина при помощи дифференциальной сканирующей калориметрии
US7622477B2 (en) * 2006-02-28 2009-11-24 Cordis Corporation Isomers and 42-epimers of rapamycin alkyl ether analogs, methods of making and using the same
US8414525B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Drug releasing coatings for medical devices
US8414526B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Medical device rapid drug releasing coatings comprising oils, fatty acids, and/or lipids
US8998846B2 (en) 2006-11-20 2015-04-07 Lutonix, Inc. Drug releasing coatings for balloon catheters
US8414910B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Drug releasing coatings for medical devices
US9737640B2 (en) 2006-11-20 2017-08-22 Lutonix, Inc. Drug releasing coatings for medical devices
US9700704B2 (en) 2006-11-20 2017-07-11 Lutonix, Inc. Drug releasing coatings for balloon catheters
US8425459B2 (en) 2006-11-20 2013-04-23 Lutonix, Inc. Medical device rapid drug releasing coatings comprising a therapeutic agent and a contrast agent
US20080276935A1 (en) 2006-11-20 2008-11-13 Lixiao Wang Treatment of asthma and chronic obstructive pulmonary disease with anti-proliferate and anti-inflammatory drugs
US20080175887A1 (en) 2006-11-20 2008-07-24 Lixiao Wang Treatment of Asthma and Chronic Obstructive Pulmonary Disease With Anti-proliferate and Anti-inflammatory Drugs
WO2010024898A2 (en) 2008-08-29 2010-03-04 Lutonix, Inc. Methods and apparatuses for coating balloon catheters
PT2365802T (pt) 2008-11-11 2017-11-14 Univ Texas Microcápsulas de rapamicina e utilização para o tratamento de cancro
US9283211B1 (en) 2009-11-11 2016-03-15 Rapamycin Holdings, Llc Oral rapamycin preparation and use for stomatitis
WO2012017449A1 (en) * 2010-08-04 2012-02-09 Meril Life Sciences Pvt. Ltd Process for preparation of novel 42-0-(heteroalkoxyalkyl) rapamycin compounds with anti-proliferative properties"
CN102268015B (zh) * 2011-08-30 2013-08-28 成都摩尔生物医药有限公司 一种依维莫司的合成方法
WO2014160328A1 (en) 2013-03-13 2014-10-02 The Board Of Regents Of The University Of Texas System Mtor inhibitors for prevention of intestinal polyp growth
CN103360411B (zh) * 2013-07-17 2015-09-30 成都雅途生物技术有限公司 依维莫司结晶提纯方法
AU2014373683B2 (en) 2013-12-31 2020-05-07 Rapamycin Holdings, Llc Oral rapamycin nanoparticle preparations and use
US9700544B2 (en) 2013-12-31 2017-07-11 Neal K Vail Oral rapamycin nanoparticle preparations
IL303660A (en) 2017-05-02 2023-08-01 Revolution Medicines Inc Rapamycin analogs as mtor inhibitors
EP3848065B1 (en) 2017-05-15 2023-07-26 C. R. Bard, Inc. Medical device with drug-eluting coating and intermediate layer
CA3098698A1 (en) 2018-05-01 2019-11-07 Revolution Medicines, Inc. C26-linked rapamycin analogs as mtor inhibitors
CN118978535A (zh) 2018-05-01 2024-11-19 锐新医药公司 作为mTOR抑制剂的C40-、C28-及C-32连接的雷帕霉素类似物
JP7262581B2 (ja) 2018-11-14 2023-04-21 ルトニックス,インコーポレーテッド 改質されたデバイス表面に薬物溶出コーティングを有する医療用デバイス
JP7487228B2 (ja) 2019-04-08 2024-05-20 バード・ペリフェラル・バスキュラー・インコーポレーテッド 改質されたデバイス表面に薬物溶出コーティングを有する医療用デバイス
JP2025522296A (ja) 2022-05-25 2025-07-15 レヴォリューション・メディスンズ,インコーポレイテッド mTOR阻害剤によりがんを処置する方法
CN116813642B (zh) * 2023-06-29 2024-04-19 浙江康润制药有限公司 一种依维莫司纯化方法
GB202415232D0 (en) 2024-10-16 2024-11-27 Nacamed As Composition

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT98990A (pt) 1990-09-19 1992-08-31 American Home Prod Processo para a preparacao de esteres de acidos carboxilicos de rapamicina
FI921595L (fi) 1991-04-17 1992-10-18 American Home Prod Rapamycinkarbamater
US5432183A (en) 1991-05-31 1995-07-11 Pfizer Inc. Use of rapamycin prodrugs as immunosuppressant agents
US5221740A (en) 1992-01-16 1993-06-22 American Home Products Corporation Oxepane isomers of rapamycin useful as immunosuppressive agents
GB9221220D0 (en) 1992-10-09 1992-11-25 Sandoz Ag Organic componds
US5516770A (en) 1993-09-30 1996-05-14 American Home Products Corporation Rapamycin formulation for IV injection
US5780462A (en) 1995-12-27 1998-07-14 American Home Products Corporation Water soluble rapamycin esters
AU2474399A (en) * 1998-01-26 1999-08-09 Mitokor Mitochondria protecting agents for treating mitochondria associated diseases
US6331547B1 (en) 1999-08-18 2001-12-18 American Home Products Corporation Water soluble SDZ RAD esters
US6277983B1 (en) 2000-09-27 2001-08-21 American Home Products Corporation Regioselective synthesis of rapamycin derivatives
US6670355B2 (en) 2000-06-16 2003-12-30 Wyeth Method of treating cardiovascular disease
ES2228932T3 (es) 2000-08-11 2005-04-16 Wyeth Procedimiento de tratamiento del carcinoma positivo de estrogenos.
CA2421485A1 (en) 2000-09-19 2002-03-28 Wyeth Water soluble rapamycin esters
US6399625B1 (en) 2000-09-27 2002-06-04 Wyeth 1-oxorapamycins
US6440991B1 (en) 2000-10-02 2002-08-27 Wyeth Ethers of 7-desmethlrapamycin
EP1419154B1 (en) 2001-08-22 2005-10-05 Wyeth Rapamycin 29-enols
CA2455311A1 (en) 2001-08-22 2003-03-06 Wyeth Rapamycin dialdehydes
WO2005010010A1 (en) * 2003-07-16 2005-02-03 Wyeth Cci-779 isomer c

Similar Documents

Publication Publication Date Title
JP2013518107A5 (enExample)
JP2013032389A5 (enExample)
JP2012255026A5 (enExample)
JP2013542247A5 (enExample)
JP2012512907A5 (enExample)
JP2011528713A5 (enExample)
JP2011528658A5 (enExample)
JP2009502743A5 (enExample)
JP2012144574A5 (enExample)
JP2014500861A5 (enExample)
JP2015505296A5 (enExample)
JP2012502037A5 (enExample)
JP2014515013A5 (enExample)
JP2013507439A5 (enExample)
JP2015024998A5 (enExample)
JP2013509429A5 (enExample)
JP2013508279A5 (enExample)
JP2017537066A5 (enExample)
JP2019526596A5 (enExample)
JP2013542261A5 (enExample)
JP2019515908A5 (enExample)
JP2013518056A5 (enExample)
JP2007302689A5 (enExample)
JP2012519182A5 (enExample)
JP2017531619A5 (enExample)